Bevacizumab and non-small-cell lung cancer

Bibliography

• JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. CA Cancer J. Clin. (2007) 57:43-66.
   PubMed Web of Science ®Google Scholar
• ALBERG AJ, SAMET JM: Epidemiology of lung cancer. Chest (2003) 123:S21-S49.
   PubMed Web of Science ®Google Scholar
• ALBERG AJ, BROCK MV, SAMET JM: Epidemiology of lung cancer: looking to the future. J. Clin. Oncol. (2005) 23:3175-3185.
   PubMed Web of Science ®Google Scholar
• NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ (1995) 311:899-909.
   Google Scholar
• BAGGSTROM MQ, SOCINSKI MA, HENSING TA et al.: Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proceedings of the 42nd ASCO Annual Meeting. Orlando, USA (2002) (Abstract 1222).
   Google Scholar
• SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. (2002) 346:92-98.
   PubMed Web of Science ®Google Scholar
• D'ADDARIO G, PINTILIE M, LEIGHL NB, FELD R, CERNY T, SHEPHERD FA: Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer: A meta-analysis of the published literature. J. Clin. Oncol. (2005) 23:2926-2936.
   PubMed Web of Science ®Google Scholar
• TISEO M, FRANCIOSI V, GROSSI F, ARDIZZONI A: Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice? Eur. J. Cancer (2006) 42(1):8-16.
   PubMed Web of Science ®Google Scholar
• PIGNON JP, TRIBODET H, SCAGLIOTTI GV et al.: Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. Proceedings of the 42nd ASCO Annual Meeting. Atlanta, USA (2006) (Abstract 7008).
   Google Scholar
• THATCHER N: Integrating new targeted agents into the treatment of non-small-cell lung cancer. Lung Cancer (2006) 54(Suppl. 2):S25-S31.
   PubMed Web of Science ®Google Scholar
• GRIDELLI C, ROSSI A, MAIONE P: New antiangiogenetic agents and non-small cell lung cancer. Crit. Rev. Oncol. Hematol. (2006) 60(1):76-86.
   PubMed Web of Science ®Google Scholar
• GRIDELLI C, MAIONE P, DEL GAIZO F et al.: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist (2007) 12(2):191-200.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):23-42.
   Google Scholar
• GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proceedings of the 41st ASCO Annual Meeting. Orlando, USA (2005).
   Google Scholar
• MILLER KD, WANG M, GRALOW J et al.: A randomized Phase III trial of paclitaxel vs paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res. Treat. (2005) 94(Suppl. 1):S6 (Abstract 3).
   Google Scholar
• SANDLER A, GRAY R, PERRY MC et al.: Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. (2006) 355:2542-2550.
   PubMed Web of Science ®Google Scholar
• ZONDOR SD: Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann. Pharmacother. (2004) 38(7):1258-1264.
   PubMed Web of Science ®Google Scholar
• HARRIS M: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. (2004) 5:292-302.
   PubMed Web of Science ®Google Scholar
• LYSENG-WILLIAMSON KA, ROBINSON DM: Bevacizumab: a review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am. J. Cancer (2006) 5(1):43-60.
   Google Scholar
• NAUMOV GN, AKSLEN LA, FOLKMAN J: Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 5(16):1779-1787.
   PubMed Web of Science ®Google Scholar
• SLEDGE GW, MILLER KD: Angiogenesis and antiangiogenic therapy. Curr. Probl. Cancer (2002) 26(1):1-60.
   PubMedGoogle Scholar
• BOEHM T, FOLKMAN J, BROWDER T, O'REILLY MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390(6658):404-407.
   PubMed Web of Science ®Google Scholar
• YU JL, RAK JW, COOMBER BL, HICKLIN DJ, KERBEL RS: Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 295(5559):1526-1528.
   PubMed Web of Science ®Google Scholar
• JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:2184-2191.
   PubMed Web of Science ®Google Scholar
• HERBST RS, TAKEUCHI H, TEICHER BA: Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother. Pharmacol. (1998) 41:497-504.
   PubMed Web of Science ®Google Scholar
• GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. (2001) 19:843-850.
   PubMed Web of Science ®Google Scholar
• MARGOLIN K, GORDON MS, HOLMGREN E et al.: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. (2001) 19:851-856.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, HERBST RS, MANEGOLD C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial–INTACT 1. J. Clin. Oncol. (2004) 22:777-784.
   PubMed Web of Science ®Google Scholar
• HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial–INTACT 2. J. Clin. Oncol. (2004) 22:785-794.
   PubMed Web of Science ®Google Scholar
• GATZEMEIER U, PLUZANSKA A, SZCZESNA A et al.: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. (2007) 25(12):1545-1552.
   PubMed Web of Science ®Google Scholar
• HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:5892-5899.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. (2001) 7(9):987-989.
   PubMed Web of Science ®Google Scholar
• WILDIERS H, GUETENS G, DE BOECK G: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer (2003) 88:1979-1986.
   PubMed Web of Science ®Google Scholar
• SLEDGE WJ: What is targeted therapy? J. Clin. Oncol. (2005) 23(8):1614-1615.
   PubMed Web of Science ®Google Scholar
• DOWLATI A, GRAY R, JOHNSON DH, SCHILLER JH, BRAHMER J, SANDLER AB: Prospective correlative assessment of biomarkers in E4599 randomized Phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC). Proceedings of the 42nd ASCO Annual Meeting. Atlanta, USA (2006) (Abstract 7027).
   Google Scholar
• SANDLER AB, JOHNSON DH, BRAHMER J et al.: Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonaryhemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). Proceedings of the 42nd ASCO Annual Meeting. Atlanta, USA (2006) (Abstract 7068).
   Google Scholar
• HERBST RS, JOHNSON DJ, MININBERG E et al.: Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J. Clin. Oncol. (2005) 23:2544-2555.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353(2):123-132.
   PubMed Web of Science ®Google Scholar
• FEHRENBACHER L, O'NEILL V, BELANI CP et al.: A Phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Proceedings of the 42nd ASCO Annual Meeting. Atlanta, USA (2006) (Abstract 7062).
   Google Scholar
• ARDIZZONI A, BONI L, TISEO M et al.: Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer. An individual patient data meta-analysis. J. Natl. Cancer Inst. (2007) 99:847-857.
   PubMed Web of Science ®Google Scholar
• HOTTA K, MATSUO K, UEOKA H et al.: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:3852-3859.
   PubMed Web of Science ®Google Scholar
• ZOJWALLA NJ, RAFTOPOULOS H, GRALLA RJ: Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2500 patients. Proceedings of the 40th ASCO Annual Meeting. New Orleans, USA (2004) (Abstract 7068).
   Google Scholar
• LE CHEVALIER T, SCAGLIOTTI G, NATALE R et al.: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 47:69-80.
   PubMed Web of Science ®Google Scholar